FOSUN PHARMA (02196) has announced that the company recently received approval from the China Securities Regulatory Commission (CSRC) for its application to issue science and technology innovation corporate bonds to professional investors. According to the approval notice, the CSRC has consented to the company's plan to publicly issue these bonds with a total face value not exceeding RMB 6 billion. The approval is valid for 24 months from the date of issuance. During this period, FOSUN PHARMA may issue the science and technology innovation corporate bonds in multiple tranches.